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Elecsys CSF biomarker immunoassays
demonstrate concordance with amyloid-
PET imaging
James D. Doecke1,2*, Larry Ward1, Samantha C. Burnham3, Victor L. Villemagne4,5, Qiao-Xin Li4, Steven Collins4,6,
Christopher J. Fowler4, Ekaterina Manuilova7, Monika Widmann8, Stephanie R. Rainey-Smith9, Ralph N. Martins10,11,
Colin L. Masters4 and the AIBL Research Group
Abstract
Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug
Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous
research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid
method to define AD pathology.
Methods: Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1–42) (Aβ42), Aβ (1–40) (Aβ40), total tau
(tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian
Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological
AD via PET imaging.
Results: Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic—area under the
curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with
individual biomarkers.
Conclusion: Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for
cognitively normal participants, further strengthening the association between these markers of AD
neuropathological burden for both developmental research studies and for use in clinical trials.
Keywords: Alzheimer’s disease, Beta-amyloid, Cerebrospinal fluid, Concordance PET, Tau
Background
Alzheimer’s disease (AD) pathology is now recognised to
evolve over an extended period before the onset of clinical
symptoms [1], with homeostatic failure of the amyloid pre-
cursor protein cleavage appearing to be the primary patho-
genic event [2–4]. The resulting accumulation of β-amyloid
(Aβ) peptides into senile plaques is coupled with the
degeneration of neurons, abnormal hyperphosphorylation
of the tau protein and formation of tau neurofibrillary
tangles [5, 6]. To date, visual assessment of Aβ positron
emission tomography (PET) scans is the only Food and
Drug Administration-approved method to support the
clinical diagnosis of AD [7]. Whilst measurement of neocor-
tical amyloid via PET is recognised as a core marker of dis-
ease pathological status, Aβ-PET imaging is costly and is
not easily amenable for application to the wider community.
Inclusion of cerebrospinal fluid (CSF), total tau (tTau)
and phosphorylated tau (181P) (pTau) in ratios with Aβ
(1–42) (Aβ42) has been shown to improve biomarker
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performance, reflecting the strong relationship between
the presence of both Aβ and tau pathologies in AD [8,
9]. Recent studies have shown good concordance be-
tween Aβ42 levels, and tTau/Aβ42 and pTau/Aβ42 ra-
tios measured in CSF using a variety of platforms,
including automated Elecsys® assays (Roche Diagnostics),
and Aβ-PET outcome obtained using different radio-
tracers in diverse study cohorts [10, 11]. Furthermore,
CSF biomarker status determined using predefined
thresholds has been shown to predict clinical decline
and progression to dementia in patients with mild cogni-
tive impairment (MCI) [10, 12]. Accordingly, the use of
CSF biomarkers to support AD diagnosis is recom-
mended in recent research diagnostic guidelines pub-
lished by the International Work Group 2 [13], as well
as the National Institute on Ageing-Alzheimer’s Associ-
ation (NIA-AA) biological framework for AD [14].
The present study aimed to provide additional evi-
dence in support of the relationship between CSF bio-
markers and the neuropathological Aβ-PET
classification, thus further contributing to the NIA-AA
research framework, which utilises the measurement of
biomarkers to define an AD continuum [14, 15]. The re-
lationship between CSF biomarkers Aβ42, Aβ (1–40)
(Aβ40), tTau and pTau (and their ratios) with the neuro-
pathological Aβ-PET classification status was evaluated
both across the full clinical disease spectrum, and in
cognitively normal controls from the highly charac-
terised Australian Imaging, Biomarkers and Lifestyle
(AIBL) study of ageing cohort.
Methods
Sample collection
This was a retrospective analysis of a sub-cohort of 202
participants from the AIBL study of ageing cohort [16],
which utilised CSF samples and available neuropatho-
logical Aβ imaging data. Samples were included from
participants who were diagnosed as either cognitively
normal (CN; n = 140), with MCI (not necessarily due to
AD, n = 33), with AD (n = 27) or with frontotemporal
dementia (FTD; n = 2) via a cognitive and a subjective
neuropsychological assessment. Prior written informed
consent was obtained from all participants, and ethical
approval was provided by all participating institutions.
CSF collection
The CSF collection protocol has been published previ-
ously [17, 18] and is aligned with the Alzheimer’s Bio-
markers Standardization Initiative [19]. Following an
overnight fast, CSF was collected in the morning by
lumbar puncture using a Temena (Polymedic®, EU)
spinal needle micro-tip (22/27G × 103mm; CAT 21922-
27). Aseptic technique was adhered to at all times, with
the participants sitting upright. CSF was collected by
either gravity or aspiration into 15-mL polypropylene
tubes (Greiner Bio-One188271). Samples were placed on
ice immediately and kept between 2 °C and 8 °C during
transport to the laboratory, and processed within 1 h.
Samples were centrifuged at 2000×g, at 4 °C for 10 min
and supernatant transferred to a fresh Greiner polypro-
pylene tube and gently inverted. Aliquots were snap-
frozen in 1-mL screw-cap 2D barcoded polypropylene
Nunc Cryotubes (NUN374088) for long-term storage;
samples were stored in liquid nitrogen vapour tanks
until use and thawed once immediately before analysis.
Immunoassays
The Elecsys β-Amyloid (1–42) CSF, Elecsys β-Amyloid
(1–40) CSF, Elecsys Total Tau CSF and Elecsys
Phospho-Tau (181P) CSF assays are electrochemilumi-
nescence immunoassays, which can be run on cobas e
601, cobas e 602 and MODULAR ANALYTICS E170
analysers. The assays have measuring ranges of 200–
1700 pg/mL (Aβ42), 0.011–39.540 ng/mL (Aβ40), 80–
1300 pg/mL (tTau) and 8–120 pg/mL (pTau). The
Elecsys β-Amyloid (1–40) assay is currently employed
for research use only. Further information on each assay,
including standardisation and analytical performance,
can be found in previous publications [20–22]. Of the
CSF biomarkers that were measured, 22% of the obser-
vations for Aβ42 were above the upper limit of the assay
measuring range. Further information regarding how
this was dealt with is shown in Additional file 1: Supple-
mentary Methods.
Amyloid-PET measurement
Aβ-PET imaging was performed with four different
radiotracers: 11C-Pittsburgh compound B (PiB),
18F-NAV4694 (NAV), 18F-Flutemetamol (FLUTE) or
18F-Florbetapir (FBP). Methodology for each tracer has
been previously described [23]. Briefly, standardised up-
take values (SUVs) were calculated via summing spatially
normalised PET images sampled using a narrow cortical
regions of interest template (reducing possible noise from
the measurement). The SUVs were then scaled to each
tracer’s recommended reference regions to define the
SUV ratio (SUVR). Reference region for NAV and PiB was
the cerebellar cortex [24, 25], for FLUTE the pons [26]
and for FBP the whole cerebellum [27]. Given that data
from the NAV and PiB tracers have almost identical dy-
namic ranges, and only one participant had measurements
from NAV alone, data from these tracers were combined
and labelled as “NAV/PiB”. Quantitative SUVR values
were dichotomised into Aβ-PET– or Aβ-PET+ based on
each tracer-specific threshold (NAV/PiB: 1.4, FLUTE: 0.62
and FBP: 1.05). Briefly, for NAV/PiB, the binary Aβ-PET
threshold was computed using a cluster analyses and
compared with thresholds previously identified by
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Clark et al. [28], for FLUTE, Thurfjell et al. used a
ROC method compared with post mortem results
[29], and lastly for FBP, Clark et al. calculated the
threshold to be the 95th percentile of the SUVR from
young healthy controls (age 35–55 years and without
cognitive impairment) [28].
Population demographic comparisons
Population demographic characteristics (gender, age,
apolipoprotein E [APOE] ε4 allele status, cognitive
scores [the preclinical Alzheimer’s cognitive composite
(PACC), Mini-Mental State Examination (MMSE) and
Clinical Dementia Rating (CDR)], PET tracer frequency
and clinical classification/diagnoses) were compared in
Aβ-PET– and Aβ-PET+ groups using chi-squared test,
independent-samples t-test and Mann–Whitney U test
where appropriate.
Comparisons of CSF biomarker means
Distribution of CSF biomarkers in groups with different
PET status were compared using the Wilcoxon signed-
rank test and generalised linear models accounting for
covariates, including age, APOE ε4 allele status, gender
and clinical classification/diagnosis. For the biomarker
comparisons between Aβ-PET status, the two partici-
pants with FTD (and ultimately not on an AD pathway)
were not included in statistical analyses.
Biomarker threshold construction
Biomarker (both individual and ratio) thresholds were
derived using the optimisation of Youden’s index [30]
within receiver operating characteristic–area under the
curve (ROC-AUC) analyses using dichotomised Aβ-PET
status as an endpoint. In addition, for Aβ42/Aβ40,
pTau/Aβ42 and tTau/Aβ42, which had clear bi-modal
distributions, unsupervised thresholds were derived
using two-component Gaussian mixture models
(GMMs). Further information on the construction of the
GMM’s and the derivation of their thresholds is shown
in Additional file 1: Supplementary Methods.
Concordance and performance of the CSF biomarkers
with Aβ-PET
Elecsys CSF assay biomarkers and their respective ratios
(Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42) were analysed
with respect to their concordance with Aβ-PET status,
irrespective of clinical classification, and within sample
with cognitively normal participants. The capability of
individual CSF biomarkers and various ratios to distin-
guish participants classified as Aβ-PET+/− was assessed
using ROC-AUC analyses. AUC values of individual bio-
markers and biomarker ratios were compared using
DeLong’s method [31]. Overall, positive and negative
percentage agreements (OPA, PPA and NPA,
respectively) with Aβ-PET status were calculated at all
derived thresholds.
Results
Sample demographics and biomarker group-wise
comparisons
Ninety participants were imaged using the NAV/PiB
tracer, 70 with the FLUTE tracer and 42 with the FBP
tracer; more participants were Aβ-PET– than Aβ-PET+
with each tracer. Overall, 38/140 (27%) CN participants,
23/33 (70%) participants with MCI and 23/27 (85%) par-
ticipants with clinically diagnosed AD had Aβ-PET+
(Table 1). Both participants with FTD were Aβ-PET–.
Participants who were Aβ-PET+ were more likely to be
male (P = 0.03), older (P = 0.01) and be APOE ε4 allele
status positive (P < 0.0001), with poorer cognitive scores
(P < 0.0003). All CSF biomarker means and medians
were significantly different between Aβ-PET groups
(P < 0.0001; Additional file 2: Supplementary Table S1),
with distributional differences between pathological and
clinical subgroups shown in Fig. 1.
CSF biomarker thresholds
Thresholds developed using the optimisation of You-
den’s index based on the complete cohort for individual
biomarkers Aβ42, tTau and pTau, and ratios Aβ42/
Aβ40, tTau/Aβ42 and pTau/Aβ42, were derived as 1054
pg/mL, 213 pg/mL, 21.3 pg/mL, and 0.064, 0.258 and
0.0183, respectively. GMM analysis for the ratios re-
sulted in the following thresholds: 0.0673 (95% confi-
dence interval [CI] 0.0612–0.0798) for Aβ42/Aβ40, 0.165
(95% CI 0.150–0.187) for tTau/Aβ42 and 0.0159 (95%
CI 0.0141–0.0184) for pTau/Aβ42. Biomarker distribu-
tion and goodness of fit are shown in Additional file 3:
Supplementary Fig. S1 and Additional file 4: Supplemen-
tary Fig. S2.
Concordance between CSF biomarkers and dichotomised
Aβ-PET
Aβ42 had the highest AUC among single biomarkers
(0.86), followed by pTau (0.84) and tTau (0.81) (Fig. 2,
Table 2). Compared with individual biomarkers, the ra-
tios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 demon-
strated a considerably higher performance (P < 0.0001),
which was similar for all ratios (AUC of 0.94).
Among the single biomarkers, Aβ42 had the highest
concordance with Aβ-PET status at the threshold opti-
mised using Youden’s index (OPA, PPA and NPA 81%,
Table 2). Aβ42/Aβ40 and pTau/Aβ42 ratios outper-
formed single biomarkers and showed similar perform-
ance at the derived thresholds (OPA was 90%, with a
PPA and an NPA close to 90%). Overall agreement to
Aβ-PET status using unsupervised thresholds was simi-
lar for Aβ42/Aβ40 (90%), and slightly lower for pTau/
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Aβ42 (86%) and tTau/Aβ42 (85%) ratios than agreement
when using thresholds derived by optimisation of You-
den’s index (Table 2). The unsupervised threshold values
were higher for Aβ42/Aβ40 and lower for the Tau/Aβ42
ratios than the optimised thresholds, resulting in slightly
higher PPA and lower NPA.
Concordance between CSF biomarkers and SUVR
We investigated the relationship between the insoluble
aggregated form of Aβ (via quantitative NAV/PiB SUVR)
and the soluble form of Aβ via CSF biomarkers Aβ42,
the Aβ42/Aβ40 ratio and the pTau/Aβ42 ratio. Given
the nature of the two different pools of Aβ, we per-
formed non-linear regression to estimate the relation-
ship. Using threshold lines for the CSF biomarker and
SUVR, Fig. 3 shows high concordance between CSF and
Aβ-PET status, and the specific relationships between
SUVR and CSF biomarkers. Additional file 5: Supple-
mentary Fig. S3 demonstrates qualitatively similar rela-
tionships for both FLUTE and FBP tracers.
Correlation structure between CSF Aβ42 and CSF tau
Scatter plots for Aβ42 versus tTau and Aβ42 versus
pTau showed two clusters (Fig. 4). The majority of Aβ-
PET– participants had values aligning close to the x-axis,
whilst those participants who were Aβ-PET+ had values
aligning close to the y-axis (Fig. 4a, b). Diagonal lines
corresponding to the thresholds derived by the optimisa-
tion of Youden’s index for ratios tTau/Aβ42 (Fig. 4a)
and pTau/Aβ42 (Fig. 4b), clearly separating participants
with positive and negative Aβ-PET status. Apparent
clusters (red for Aβ-PET+ and blue for Aβ-PET–) dem-
onstrated the ability of the marker to align with neuro-
pathological amyloid load.
PET concordance analysis split by tracer
Given that four different tracers were used within this study
and that the relationship between PET tracer and corre-
lated biomarker has previously been shown to vary by
tracer [32, 33], all binary PET comparisons were performed
using tracer-specific PET status. Whilst the distribution of
Aβ-PET+/− participants was different between tracers, re-
sults of ROC-AUC analysis were similar (Additional file 6:
Supplementary Table S2), with small differences in per-
formance possibly due to the limited sample sizes.
PET concordance analysis in CN samples
Biomarker thresholds developed based on the optimisa-
tion of Youden’s index were 1046 pg/mL for Aβ42, and
0.064, 0.184 and 0.0186 for Aβ42/Aβ40, tTau/Aβ42 and
pTau/Aβ42, respectively. Agreement OPA was 83% for
Aβ42 and was 89%, 89% and 90% for Aβ42/Aβ40, tTau/
Aβ42 and pTau/Aβ42, respectively (Additional file 7: Sup-
plementary Table S3). We observed a decrease in PPA
and NPA of only 1% for Aβ42/Aβ40 and pTau/Aβ42 ra-
tios, with very similar optimised threshold values com-
pared with the whole population. The threshold for tTau/
Aβ42 was slightly lower for CN participants, resulting in a
higher PPA (92% vs 83% in the whole population) and
lower NPA (87% vs 97% in the whole population).
Table 1 Study population demographic characteristics, including comparisons between Aβ-PET groups
Characteristic Total sample Aβ-PET– Aβ-PET+ P value
n (%) 202 (100) 118 (58) 84 (42) –
Gender male, n (%) 100 (50) 51 (43) 49 (58) 0.0340
Mean (SD) age, years 73.5 (6.2) 72.5 (6.2) 74.8 (6.0) 0.0110
APOE ε4 allele status carriage, n (%) 64 (32) 24 (21) 40 (48) < 0.0001
Mean (SD) PACC score − 3.0 (6.8) − 0.5 (4.2) − 6.8 (8.1) < 0.0001
Median (IQR) MMSE score 28 (4.0) 29 (2.0) 27 (4.2) 0.0002
Median (IQR) CDR score 0 (2.4) 0 (0) 0.5 (3.2) 0.0002
Tracer, n (%) 0.048
NAV/PiB 90 (44) 46 (23) 44 (22) –
FLUTE 70 (35) 41 (20) 29 (14) –
FBP 42 (21) 31 (15) 11 (6) –
Clinical classification, n (%) < 0.0001
CN 140 (70) 102 (51) 38 (19) –
MCI 33 (16) 10 (5) 23 (11) –
AD 27 (13) 4 (2) 23 (11) –
FTD 2 (1) 2 (1) 0 (0) –
Abbreviations: Aβ, β-amyloid; AD, Alzheimer’s disease; APOE, apolipoprotein E; CDR, Clinical Dementia Rating; CN, cognitively normal; FBP, 18F-florbetapir; FLUTE,
18F-flutemetamol; FTD, frontotemporal dementia; IQR, interquartile range; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NAV,
18F-NAV4694; PACC, Preclinical Alzheimer Cognitive Composite; PET, positron emission tomography; PiB, 11C-Pittsburgh compound B; SD, standard deviation
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Fig. 1 (See legend on next page.)
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Discussion
The current study shows high concordance between
neuropathological AD CSF biomarkers and Aβ-PET
classification in both the overall sub-cohort of AIBL, and
in the subgroup of CN participants.
When comparing Aβ-PET concordance for the CSF bio-
marker ratios across the complete cohort, irrespective of
clinical classification, the GMM unsupervised thresholds re-
sulted in higher PPA and lower NPA than the ROC-AUC
thresholds. The unsupervised thresholds distinguish AD-like
from non-AD-like biomarker profiles. In our study, 90% of
participants with AD-like CSF in the Aβ42/Aβ40 ratio were
Aβ-PET+, and 90% of participants with non-AD-like CSF in
the Aβ42/Aβ40 ratio were Aβ-PET–. The corresponding
numbers for the pTau/Aβ42 ratio were 90% and 91%, and
for the tTau/Aβ42 ratio were 83% and 97%. Only 3–10% of
patients with non-AD-like biomarker profiles were Aβ-
PET+, but 10–17% of patients with pathological CSF bio-
marker profiles were Aβ-PET–. This finding is consistent
with the notion that CSF biomarkers are able to identify
participants at risk of developing clinical AD much earlier
than Aβ-PET. However, in our cohort, this notion could not
be confirmed due to the very small number of participants
whose diagnosis changed during the follow-up period.
CSF Tau/Aβ42 and Aβ42/Aβ40 ratios demonstrated
greater concordance with Aβ-PET status compared with
individual biomarkers. In particular, OPA of the Tau/
Aβ42 (90%) and Aβ42/Aβ40 (90%) ratios outperformed
Aβ42 alone (81%). These results are consistent with pre-
viously published PET concordance studies using Elecsys
assays. For example, concordance analysis with visual
PET outcome in a subset of patients with mild cognitive
symptoms from the Swedish BioFINDER cohort showed
that the CSF tTau/Aβ42 and pTau/Aβ42 ratios have a
higher OPA (90%) compared with Aβ42 alone (80%)
[10]. Similarly, in a Korean cohort of patients with AD,
concordance with NAV/PiB, PET SUVR was improved
using the tTau/Aβ42 ratio (OPA, 92.5) over Aβ42 alone
(OPA, 85.2%) [34]. Consistent with these findings, a re-
cent roadmap for AD biomarkers also identified the
(See figure on previous page.)
Fig. 1 Box and whisker plots of CSF biomarkers by Aβ-PET status and clinical classification. a Aβ42, b Aβ42/Aβ40 ratio, c tTau, d tTau/Aβ42 ratio,
e pTau and f pTau/Aβ42 ratio. Dashed lines represent threshold values for each CSF biomarker as calculated via ROC analyses. Abbreviations: Aβ,
β-amyloid; Aβ42, β-amyloid (1–42); Aβ42/Aβ40, β-amyloid (1–42)/β-amyloid (1–40) ratio; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; HC,
healthy controls; MCI, mild cognitive impairment; PET, positron emission tomography; pTau, phosphorylated tau (181P); pTau/Aβ42,
phosphorylated tau (181P)/β-amyloid (1–42) ratio; ROC, receiver operating characteristic; tTau, total tau; tTau/Aβ42, total tau/β-amyloid (1–42) ratio
Fig. 2 ROC curves of a individual CSF biomarkers and b biomarker ratios to predict Aβ-PET status. AUC statistics are presented for each
biomarker. Abbreviations: Aβ, β-amyloid; Aβ42, β-amyloid (1–42); Aβ42/Aβ40, β-amyloid (1–42)/β-amyloid (1–40) ratio; AUC, area under the curve;
CSF, cerebrospinal fluid; PET, positron emission tomography; pTau, phosphorylated tau (181P); pTau/Aβ42, phosphorylated tau (181P)/β-amyloid
(1–42) ratio; tTau, total tau; tTau/Aβ42, total tau/β-amyloid (1–42) ratio
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greater diagnostic utility of CSF biomarker ratios [15].
Possible explanations for the better performance of CSF
biomarker ratios over Aβ42 alone have been discussed
previously [10]. Briefly, Tau/Aβ42 ratios combine the
two core biomarkers of the principal pathological pro-
cesses, underlying AD into a single marker; combining
measurements of two different proteins may compensate
for natural fluctuations in the levels of each protein; and
the temporal profile of Aβ42 and tau biomarkers differ,
with Aβ42 considered to be an earlier metric of disease
development than tau [35].
Similar to results from Schindler et al. [11], in cogni-
tively normal patients assessed using PET with a cut-off
of 1.42, performance of the pTau and tTau ratios with
Aβ42 was very close to that of the Aβ42/40 ratio (OPA
AIBL Aβ42/40: 90%, OPA ADRC Aβ42/40: 86%; OPA
AIBL pTau/Aβ42: 91%, OPA ADRC pTau/Aβ42: 89%;
OPA AIBL tTau/Aβ42: 91%, OPA ADRC tTau/Aβ42:
87%). Given the stage at which a participant is measured
as Aβ-PET+, it is likely that the amyloid accumulation
has caused synaptic damage, causing Tau to be released
and accumulate into tangles (as a secondary event). As
such the CSF Tau biomarkers are increasing and the
CSF Aβ42 is simultaneously decreasing.
Given the inherent relationship between CSF biomarkers
and Aβ-PET status, we investigated the relationship between
NAV/PiB SUVR and the CSF biomarkers Aβ42, Aβ42/Aβ40
ratio, tTau/Aβ42 ratio and pTau/Aβ42 ratio. The Tau/Aβ42
Table 2 ROC curve results—CSF biomarkers for prediction of Aβ-PET status
Biomarker AUC (95% CI) Threshold Optimisation method PPA (%) NPA (%) OPA (%)
Aβ42 0.86 (0.81–0.92) 1054 pg/mL Youden 81 81 81
tTau 0.81 (0.75–0.87) 213 pg/mL Youden 86 66 75
pTau 0.84 (0.78–0.89) 21.3 pg/mL Youden 81 77 79
Aβ42/Aβ40 0.94 (0.89–0.98) 0.064 Youden 90 90 90
0.0673 GMM 92 88 90
tTau/Aβ42 0.94 (0.90–0.98) 0.258 Youden 83 97 91
0.165 GMM 92 80 85
pTau/Aβ42 0.94 (0.90–0.98) 0.0183 Youden 90 91 91
0.0159 GMM 90 83 86
Abbreviations: Aβ, β-amyloid; Aβ42, β-amyloid (1–42); Aβ42/Aβ40, β-amyloid (1–42)/β-amyloid (1–40) ratio; AUC, area under the curve; CI, confidence interval; CSF,
cerebrospinal fluid; GMM, Gaussian mixture model; NPA, negative percentage agreement; OPA, overall percentage agreement; PET, positron emission tomography;
PPA, positive percentage agreement; pTau, phosphorylated tau (181P); pTau/Aβ42, phosphorylated tau (181P)/β-amyloid (1–42) ratio; ROC, receiver operating
characteristic; tTau, total tau; tTau/Aβ42, total tau/β-amyloid (1–42) ratio
Fig. 3 CSF biomarkers versus NAV/PiB SUVR for a Aβ42, threshold: 1054, b Aβ42/Aβ40 ratio, threshold: 64.0 (× 0.001) and c pTau/Aβ42
ratio,threshold: 0.018. Solid lines in plots a and b represent the non-linear relationship between CSF biomarkers and NAV/PiB SUVR. The solid line
in plot c represents the linear relationship between NAV/PiB SUVR and pTau/Aβ42. Grey shaded areas represent the 95% CI around the solid line.
Grey dashed lines represent thresholds for SUVR (vertical) and CSF (horizontal) biomarkers. Red symbols represent Aβ-PET+; blue symbols
represent Aβ-PET–; circles represent CN participants; triangles represent participants with MCI; squares represent participants with AD.
Abbreviations: Aβ, β-amyloid; Aβ42, β-amyloid (1–42); Aβ42/Aβ40, β-amyloid (1–42)/β-amyloid (1–40) ratio; AD, Alzheimer’s disease; CI, confidence
interval; CN, cognitively normal; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; NAV, 18F-NAV4694; PET, positron emission tomography;
PiB, 11C-Pittsburgh compound B; pTau/Aβ42, phosphorylated tau (181P)/β-amyloid (1–42) ratio; SUVR, standardised uptake value ratio
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ratios demonstrated a slightly higher overall agreement than
the Aβ42/Aβ40 ratio, albeit not significant, and both ratios
outperformed Aβ42 alone. Similar relationships were ob-
served using FLUTE and FBP tracers.
Good concordance between CSF biomarkers and Aβ-
PET classification was also observed in the subset of par-
ticipants with normal cognition, and the degree of con-
cordance was equivalent to that observed in the whole
study population, differing only by approximately 1% in
terms of NPA and PPA for the majority of biomarkers.
These results support the opinion that AD pathogenesis is
progressive and continuous, and changes in biomarkers
occur prior to the onset of clinical symptoms. Our find-
ings in CSF samples from AIBL study participants are
consistent with those previously reported in other clinical
cohorts, including BioFINDER and Alzheimer’s Disease
Neuroimaging Initiative (ADNI). Given the large propor-
tion of cognitively normal elderly in the AIBL population,
as compared with BioFINDER and ADNI, which had lar-
ger sample sizes in their MCI and AD populations, it is in-
teresting that similar results overall were identified across
these groups. This adds to the current knowledge that
these neuropathological CSF biomarkers are highly pre-
dictive of amyloid plaques, irrespective of clinical stage.
This study presents research-based thresholds for CSF
biomarkers for the separation of Aβ-PET groups similar
to that of Hansson et al. [10] and Schindler et al. [11];
however, due to differences in sample handling and pre-
analytical procedures, which may potentially affect mea-
sured CSF biomarker levels and biomarker thresholds
[36, 37], the thresholds are not directly comparable.
Whilst this presents a problem for direct comparison of
thresholds, the performance of this and other studies all
point towards strong agreement between the soluble Aβ
and Tau as measured by CSF along with the measure-
ment of the insoluble amyloid as measured by PET MRI.
Limitations of the present study include that PET
SUVR is a proxy for histopathology, which is the current
“gold standard” for establishing amyloid status. Add-
itionally, the current research study used several radio-
tracers; this is however, reflective of both true clinical
practice and research studies whereby funding con-
straints affect the ability to scan patients/participants.
Reassuringly, results of the ROC-AUC analyses here
were similar across the tracers. Retrospective samples
were used from a small subset of participants, potentially
reducing the reliability of our findings. The NPA and
PPA values calculated at cut-offs derived by optimisation
of Youden’s index may be overoptimistic and should be
validated in an independent data set.
A small number of participants who were diagnosed
with AD-dementia or MCI did not have both tau and
amyloid pathology (e.g. negative Aβ-PET, normal CSF
Aβ42 and abnormal CSF tau levels), and thus neuro-
pathological AD was likely not the cause of their cogni-
tive impairment. Of interest, two participants with FTD
were both Aβ-PET−, demonstrating the absence of AD
pathology in this type of dementia. As a strength, the
study was therefore representative of a true population
and shows the important role of biomarkers in differen-
tiating AD from other forms of neurodegenerative
diseases. Finally, the study is based on a single longitudinal
research cohort, employing uniform approaches to all
aspects, including CSF specimen handling, leaving some
uncertainty about the generalisability of the findings to
more diverse populations with a higher likelihood of less
systematic technical rigour in relation to the biomarkers.
Conclusion
The AD CSF biomarkers showed high concordance with
Aβ-PET status in a cohort of individuals from the AIBL
study. All three biomarker ratios (Aβ42/Aβ40, tTau/Aβ42
Fig. 4 CSF biomarker relationships for a tTau versus Aβ42 and b pTau versus Aβ42. Diagonal lines represent the split between the two clusters.
Horizontal and vertical lines represent the cut-offs. Red symbols represent Aβ-PET+; blue symbols represent Aβ-PET–; circles represent cognitively
normal participants; triangles represent participants with MCI; squares represent participants with AD. Abbreviations: Aβ, β-amyloid; Aβ42, β-
amyloid (1–42); AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; PET, positron emission tomography; pTau,
phosphorylated tau (181P); tTau, total tau
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and pTau/Aβ42) demonstrated superior performance to
Aβ42 alone. These results further strengthen evidence
supporting the potential diagnostic utility of CSF bio-
markers, including the Elecsys platform biomarkers for
identification of individuals at risk of AD in prodromal/
preclinical populations with normal cognition and early
symptomatic patients, as well as for participant selection
in therapeutic trials.
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